Carboplatin

Generic Name: Carboplatin

Brand Names: Paraplatin

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₂N_₂O_₄Pt

CAS Number: 41575-94-4

Unique Ingredient Identifier: BG3F62OND5

Background: Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.

Carboplatin was granted FDA approval on 3 March 1989.

Indication: Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.

Associated Conditions: Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma

Associated Therapies: Conditioning regimens for allogeneic stem cell transplantation therapy

Clinical Trials

Everolimus, Carboplatin, and Paclitaxel in Locally Advanced Head and Neck Cancer That Cannot Be Removed by Surgery

Phase 1

Completed

Conditions: Head and Neck Cancer

Interventions: Drug: carboplatin
Drug: RAD001
Drug: paclitaxel

First Posted Date: 2011-04-11

Last Posted Date: 2016-02-10

Lead Sponsor: GERCOR - Multidisciplinary Oncology Cooperative Group

Target Recruit Count: 49

Registration Number: NCT01333085

Locations: 🇫🇷
Hopital Beaujon, Clichy, France
🇫🇷
Centre Léon Berard, Lyon, France
🇫🇷
Institut Curie, Paris, France

and more 2 locations

PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy

Phase 2

Completed

Conditions: Adenocarcinoma of the Gastroesophageal Junction
Esophageal Cancer

Interventions: Drug: Oxaliplatin
Drug: Leucovorin Calcium
Drug: Fluorouracil
Drug: Carboplatin
Drug: Paclitaxel
Procedure: Positron Emission Tomography
Procedure: Computed Tomography
Radiation: Radiation Therapy

First Posted Date: 2011-04-11

Last Posted Date: 2023-04-13

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 257

Registration Number: NCT01333033

Locations: 🇺🇸
Diagnostic and Treatment Center, Weston, Wisconsin, United States
🇺🇸
Fletcher Allen Health Care - University Health Center Campus, Burlington, Vermont, United States
🇺🇸
Saint Joseph's Hospital, Marshfield, Wisconsin, United States

and more 65 locations

Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel

Phase 2

Completed

Conditions: Ovarian Cancer Recurrent

Interventions: Drug: Placebo
Drug: Ombrabulin (AVE8062)
Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2011-04-11

Last Posted Date: 2015-12-21

Lead Sponsor: Sanofi

Target Recruit Count: 154

Registration Number: NCT01332656

Locations: 🇺🇸
Investigational Site Number 840002, Boston, Massachusetts, United States
🇨🇿
Investigational Site Number 203004, Zlin, Czech Republic
🇷🇺
Investigational Site Number 643003, Moscow, Russian Federation

and more 35 locations

RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation

Phase 4

Completed

Conditions: Carcinoma, Large Cell
Neuroendocrine Tumors

Interventions: Drug: RAD001
Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2011-03-17

Last Posted Date: 2016-03-30

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 49

Registration Number: NCT01317615

Locations: 🇩🇪
Novartis Investigative Site, Ulm, Germany

Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer

Phase 2

Completed

Conditions: Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma
Recurrent Metastatic Squamous Neck Cancer With Occult Primary
Recurrent Salivary Gland Cancer
Recurrent Squamous Cell Carcinoma of the Hypopharynx
Recurrent Squamous Cell Carcinoma of the Larynx
Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity
Recurrent Squamous Cell Carcinoma of the Nasopharynx
Recurrent Squamous Cell Carcinoma of the Oropharynx
Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity
Recurrent Verrucous Carcinoma of the Larynx

Interventions: Biological: cetuximab
Drug: paclitaxel
Drug: carboplatin
Drug: erlotinib hydrochloride
Other: laboratory biomarker analysis

First Posted Date: 2011-03-16

Last Posted Date: 2018-02-26

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 24

Registration Number: NCT01316757

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Univesity of Rochester Medical Center, Rochester, New York, United States
🇺🇸
UT Southwestern Medical Center, Dallas, Texas, United States

A Study of the Safety and Pharmacology of GDC-0980 in Combination With Either Paclitaxel and Carboplatin (With or Without Bevacizumab) or Pemetrexed and Cisplatin in Patients With Solid Tumors

Phase 1

Completed

Conditions: Solid Cancers

Interventions: Drug: GDC-0980
Drug: bevacizumab
Drug: carboplatin
Drug: cisplatin
Drug: paclitaxel
Drug: pemetrexed

First Posted Date: 2011-02-23

Last Posted Date: 2016-11-02

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 75

Registration Number: NCT01301716

Carboplatin and Bevacizumab for Recurrent Ependymoma

Phase 2

Completed

Conditions: Anaplastic Ependymoma
Ependymoma

Interventions: Drug: Carboplatin
Drug: Bevacizumab

First Posted Date: 2011-02-15

Last Posted Date: 2022-05-17

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 35

Registration Number: NCT01295944

Locations: 🇺🇸
Massachusetts General Hospital/Dana Farber, Boston, Massachusetts, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Cisplatin and Radiation Therapy Followed by Paclitaxel and Carboplatin in Treating Patients With Stage IB-IVA Cervical Cancer

Phase 1

Conditions: Cervical Adenocarcinoma
Cervical Adenosquamous Carcinoma
Cervical Squamous Cell Carcinoma, Not Otherwise Specified
Stage IB Cervical Cancer AJCC v6 and v7
Stage IIA Cervical Cancer AJCC v7
Stage IIB Cervical Cancer AJCC v6 and v7
Stage IIIA Cervical Cancer AJCC v6 and v7
Stage IIIB Cervical Cancer AJCC v6 and v7
Stage IVA Cervical Cancer AJCC v6 and v7

Interventions: Drug: Carboplatin
Drug: Cisplatin
Radiation: External Beam Radiation Therapy
Radiation: Internal Radiation Therapy
Drug: Paclitaxel

First Posted Date: 2011-02-14

Last Posted Date: 2019-03-12

Lead Sponsor: Gynecologic Oncology Group

Target Recruit Count: 45

Registration Number: NCT01295502

Locations: 🇺🇸
Summa Akron City Hospital/Cooper Cancer Center, Akron, Ohio, United States
🇺🇸
Case Western Reserve University, Cleveland, Ohio, United States
🇺🇸
MetroHealth Medical Center, Cleveland, Ohio, United States

and more 11 locations